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IL-17A plays an important role in respiratory disease and is a known regulator of pulmonary inflammation and immunity. Recent studies have linked IL-17A with exacerbation in asthma and COPD. We have shown that the enzyme cyclooxygenase-2 (COX-2) and its prostanoid products, prostaglandin E2 (PGE2) in particular, are key contributors in in vitro models of infectious exacerbation; however, the impact of IL-17A was not known. We address this herein and show that IL-17A induces a robust and sustained upregulation of COX-2 protein and PGE2 secretion from airway smooth muscle (ASM) cells. COX-2 can be regulated at transcriptional, post-transcriptional and/or post-translational levels. We have elucidated the underlying molecular mechanisms responsible for the sustained upregulation of TNF-induced COX-2 by IL-17A in ASM cells and show that is not via increased COX-2 gene expression. Instead, TNF-induced COX-2 upregulation is subject to regulation by the proteasome, and IL-17A acts to increase TNF-induced COX-2 protein stability as confirmed by cycloheximide chase experiments. In this way, IL-17A acts to amplify the COX-2-mediated effects of TNF and greatly enhances PGE2 secretion from ASM cells. As PGE2 is a multifunctional prostanoid with diverse roles in respiratory disease, our studies demonstrate a novel function for IL-17A in airway inflammation by showing for the first time that IL-17A impacts on the COX-2/PGE2 pathway; molecules known to contribute to disease exacerbation. 





IL-17A orchestrates airway inflammation in asthma and COPD. This pivotal cytokine is found in elevated levels in respiratory diseases, including severe asthma () and COPD  ADDIN EN.CITE (), and directs pulmonary immunity and inflammation (). Recent evidence has implicated IL-17A as a key driver of disease exacerbation in severe asthma  ADDIN EN.CITE () and in vivo models of infectious exacerbation  ADDIN EN.CITE (). 
We have modelled viral and bacterial exacerbation in vitro utilizing primary cultures of airway smooth muscle (ASM) cells and demonstrated the critical role played by cyclooxygenase-2 (COX-2) and its prostanoid products, prostaglandin E2 (PGE2) in particular. COX-2 is an inducible enzyme that can be rapidly, but transiently, upregulated by a diverse range of stimuli, including pro-inflammatory mediators and infectious stimuli acting via toll-related receptors (TLRs)  ADDIN EN.CITE (). Although IL-17A has been implicated in infectious exacerbation in respiratory disease, its impact on COX-2/PGE2 has not been explored to date.












Human bronchi were obtained from patients undergoing surgical resection for carcinoma or lung transplant donors in accordance with procedures approved by the Sydney South West Area Health Service and the Human Research Ethics Committee of the University of Sydney. ASM cells were dissected and purified as previously described by Johnson et al. (). ASM cells were cultured until confluent in accordance with established culture conditions (). Briefly, primary ASM cells were plated at a density of 1x104 cells/cm2 and media replenished every 72 h. After 1 week of culture at 37oC and 5% CO2, cells were confluent and underwent a 48 h growth arrest period in DMEM supplemented with sterile BSA (0.1% v/v). A minimum of three different ASM primary cell lines were used for each experiment.

Chemicals
TNF and IL-17A were purchased from R&D Systems (Minneapolis, MN) and celecoxib from Cayman Chemical Company (Ann Arbor, MI). Unless otherwise specified, all chemicals were from Sigma-Aldrich (St. Louis, MO). 

PGE2 assay
PGE2 was measured by enzyme immunoassay (Prostaglandin E2 EIA 514010: Cayman Chemical Company) according to the manufacturer’s instructions.    

Real-time RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Australia, Doncaster, VIC, Australia) and reverse transcribed using the RevertAid First strand cDNA Synthesis Kit (Fermentas Life Sciences, Hanover, MD). Real-time RT-PCR was performed on an ABI Prism 7500 with COX-2 (Hs0015133_m1) TaqMan® Gene Expression Assays and the eukaryotic 18S rRNA endogenous control probe (Applied Biosystems, Foster City, CA) subjected to the following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 s, 60°C for 1 min, 40 cycles and mRNA expression (fold increase) quantified by delta delta Ct calculations. 

Western blotting
SDS-PAGE was performed with 8% (COX-2) or 12% (IB-α) separating gels and proteins were electrophoretically transferred to nitrocellulose membranes (Pall Corporation, Port Washington, NY). Western blotting was performed using mouse monoclonal antibodies against COX-2 (sc-19999) or rabbit polyclonal antibodies against IB-α (sc-371), compared to α-tubulin as the loading control (clone DM 1A: sc-32293). All primary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA) and were detected with goat anti-mouse or goat anti-rabbit HRP–conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA) and visualized by enhanced chemiluminescence (PerkinElmer, Wellesley, MA).

cAMP assay
Desensitization of the β2-adrenergic receptor was assessed by measuring production of cAMP in response to stimulation with the β2-agonists salbutamol (10 µM) and formoterol (10 nM) for 15 min, in the presence of the pan-phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX: 30 min pretreatment at 10 μM), in accordance with previously published methods  ADDIN EN.CITE (, ). cAMP was measured by enzyme immunoassay (cAMP EIA 581001: Cayman Chemical Company) according to the manufacturer’s instructions.

Statistical analysis




IL-17A augments TNF-induced PGE2 secretion, but does not increase TNF-induced COX-2 mRNA expression
IL-17A is known to modulate airway inflammation in respiratory disease. Our recent studies in ASM cells have revealed the important role played by the prostanoid PGE2 in mediating β2-adrenergic receptor desensitization  ADDIN EN.CITE (, ). This occurs in a COX-2-dependent manner and to date, whether IL-17A exerts an influence on COX-2 upregulation/PGE2 secretion in ASM cells was unknown. To address this, we first treated cells with IL-17A (10 ng/ml) alone, or in combination with TNF (10 ng/ml), and measured the temporal kinetics of PGE2 secretion, compared to vehicle-treated cells. As shown in Figure 1A, IL-17A alone had no effect on PGE2 secretion, while stimulation with TNF, a known inducer of PGE2  ADDIN EN.CITE (, , ), resulted in significantly elevated levels of PGE2 by 24 h (P<0.05). Importantly, when cells were stimulated with TNF in the presence of IL-17A, PGE2 secretion was robustly enhanced with significant and sustained amounts of PGE2 secretion observed as early as 4 h (Figure 1A: P<0.05). 
We were intrigued to understand the underlying molecular mechanism. PGE2 is produced by the action of the enzyme COX-2. COX-2 can be upregulated by increased gene expression (via transcriptional or post-transcriptional means), and/or post-translationally via increased protein stability. To date, the effect of IL-17A on COX-2 gene expression in ASM cells was unknown. To understand the mechanism responsible for the upregulation of TNF-induced PGE2 secretion in ASM cells by IL-17A, we examined the impact of IL-17A on COX-2 mRNA expression and whether it played a role in potentiating the effects of TNF. In Figure 1B we demonstrate the temporal regulation of COX-2 mRNA expression; and, in corroboration of our earlier studies  ADDIN EN.CITE (, ), TNF increases COX-2 mRNA expression with significant expression (P<0.05) observed as early as 1 h, sustained until 4 h, and then shown to decline by 8 h. As predicted by the lack of PGE2 secretion, IL-17A alone did not induce COX-2 mRNA expression. More unexpectedly however, IL-17A added in combination with TNF did not enhance COX-2 mRNA expression. 

IL-17A increases TNF-induced COX-2 protein upregulation
Because these data indicate that the augmentation of TNF-induced PGE2 by IL-17A is not via potentiation of TNF-induced COX-2 mRNA expression, we then examined COX-2 protein upregulation after growth-arrested ASM cells were treated with vehicle, IL-17A, TNF, or IL-17A + TNF (Figure 2A). In accordance with the lack of effect of IL-17A on COX-2 mRNA expression and PGE2 secretion, IL-17A alone did not induce COX-2 protein (data not shown). As shown by Western blotting (Figure 2A), there was a peak of TNF-induced protein upregulation observed at 8 h, that later declined at 24 h. This was confirmed by densitometric analysis (Figure 2B: P<0.05), where TNF induced a significant 10.6±5.5-fold increase in COX-2 protein upregulation at 8 h, that then declined by 24 h. Thus, the temporal kinetics of COX-2 protein upregulation after TNF stimulation (Figure 2) aligns well with COX-2 mRNA expression (Figure 1B): that is, COX-2 mRNA induced by TNF stimulation was consequently translated into COX-2 protein; albeit in a transient manner. In contrast, while IL-17A had no effect on TNF-induced COX-2 mRNA (Figure 1B), IL-17A robustly upregulated TNF-induced COX-2 protein in a sustained manner (Figure 2). Western blotting revealed that IL-17A enhanced TNF-induced COX-2 protein upregulation at 4 h, 8 h and 24 h (Figure 2A). This was confirmed by densitometric analysis (Figure 2B: P<0.05). Notably, at 24 h, IL-17A added in combination with TNF induced a 33.8±1.7-fold increase in COX-2 protein, in comparison to 3.9±1.7-fold with TNF alone at the same time point (Figure 2B: P<0.05). Taken together, our data shows that IL-17A increases TNF-induced COX-2 protein stability, but not TNF-induced COX-2 mRNA gene expression in ASM cells.

Proteasome inhibitors increase TNF-induced COX-2 protein and PGE2 secretion
COX-2 is an inducible gene known to be expressed by a wide variety of inflammatory stimuli, but COX-2 protein upregulation in cells is typically transient (reviewed in ()). Post-translational regulatory mechanisms have begun to emerge  ADDIN EN.CITE (, ), and in cell types apart from ASM, degradation by the 26S proteasome has been shown to play a role  ADDIN EN.CITE ().  Our data suggests that IL-17A increases the stability of COX-2 protein induced by TNF. But to date, whether protein stability contributes to steady-state levels of COX-2 protein in ASM cells was unknown. Thus, in order to show that TNF-induced COX-2 protein is subject to proteasomal degradation in ASM, we pretreated cells with two inhibitors of the proteasome - bortezomib and MG-132 – and examined whether TNF-induced COX-2 protein levels are increased. Growth-arrested ASM cells were pretreated for 30 min with bortezomib (10 nM) or MG-132 (10 µM), before stimulation with TNF for up to 24 h. In the representative Western blots shown in Figure 3A, blocking the proteasome with bortezomib or MG-132 enhances COX-2 protein upregulation induced by TNF. This is confirmed by densitometric analysis in Figure 3B, where the level of TNF-induced COX-2 protein at 24 h (3.3±0.9-fold) was significantly increased by bortezomib to 8.9±1.8-fold and MG-132 to 19.5±2.5-fold (P<0.05). These data support our assertion that TNF-induced COX-2 is degraded by the proteasome. Thus, it follows that if COX-2 protein stability is enhanced, production of COX-2-mediated prostanoid products, including PGE2, will be increased. In support, Figure 3C shows that the TNF-induced PGE2 secretion at 24 h is significantly enhanced after bortezomib or MG-132 pretreatment (P<0.05).

IL-17A enhances TNFα-induced COX-2 protein stability 
To confirm that IL-17A enhances TNFα-induced COX-2 protein stability, we performed cycloheximide chase experiments. We treated growth-arrested ASM cells for 8 h with TNFα ± IL-17A (to achieve peak levels of COX-2 steady-state protein production; as demonstrated earlier in Figure 2A). Cells were then washed and treated with cycloheximide (20 µg/ml) to block further protein translation; in accordance with previous published methods  ADDIN EN.CITE (). Cell lysates were prepared at 1, 2, 4, 6, and 16 h after the addition of cycloheximide (designated as 0 h). COX-2 was then quantified by Western blotting (normalized to α-tubulin), analysed by densitometry and expressed as a percentage of COX-2 at 0 h. As shown in Figure 4, the percentage of COX-2 remaining 2, 4, 6 and 16 h after protein translation had been halted by cycloheximide treatment was significantly greater in cells treated with IL-17A + TNFα, compared to TNFα alone (P<0.05). Thus, IL-17A enhances TNFα-induced protein stability. Future studies examining the molecular mechanisms responsible for enhanced COX-2 protein stability exerted by IL-17A are warranted, but herein we were intrigued to examine whether IL-17A stabilizes other proteins relevant to airway inflammatory diseases. To address this, we focussed on IB-α, the inhibitory protein regulated by the 26S proteasome that complexes with pro-inflammatory NF-B to hold it in check. When ASM cells are stimulated by TNFα, IB-α protein was degraded (as shown in Figure 5, and in confirmation of our previous reports  ADDIN EN.CITE (, )). NF-B is then released from the inhibitory complex and is now competent to activate transcriptional pathways and promote ASM synthetic function  ADDIN EN.CITE (, )).  Interestingly, we show that TNFα-induced degradation of inhibitory IB-α was unaffected by IL-17A (Figure 5). These results address, in part, the specificity of the IL-17A-mediated COX-2 response by showing that under identical conditions, other proteins shown to be regulated proteasomally (utilizing IB- as an example) are unaffected by IL-17A. 

Heterologous β2-adrenergic desensitization as measured by inhibition of β2-agonist-induced cAMP production in ASM cells: effects of IL-17A ± TNF










In this study we show that TNF upregulates COX-2 by inducing mRNA expression in ASM cells. We reveal that the transient upregulation of COX-2 protein induced by TNF in ASM cells is due to degradation by the proteasome. We show that two inhibitors of the 26S proteasome - bortezomib (Velcade) and MG-132 - can block degradation of TNF-induced COX-2 and enhance PGE2 production. We have shown that IL-17A acts to increase TNF-induced PGE2 by enhancing COX-2 protein stability, but not COX-2 gene expression. This is a novel finding in ASM cells and this new knowledge improves our understanding of how IL-17A impacts on the COX-2/PGE2 regulatory network.
Given the impact of the COX-2 enzyme in health and disease, it unsurprisingly that there are multiple molecular mechanisms that allow COX-2, and its resultant prostanoids, to be controlled in precise spatiotemporal regulatory networks. COX-2 gene expression is known to be regulated transcriptionally () and/or post-transcriptionally via increased mRNA stability  ADDIN EN.CITE (). Somewhat more recently, mechanisms responsible for the post-translational regulation of COX-2 protein stability have begun to emerge  ADDIN EN.CITE (, , ). IL-17A is a “fine-tuning cytokine”, often without direct effects alone; it can profoundly modulate the action of cytokines in an additive or synergistic manner. Although IL-17A is known to increase gene expression by enhancing mRNA stability (), and we have previously shown that IL-17A significantly enhanced TNF-induced IL-6 and IL-8 mRNA expression via post-transcriptional means in ASM cells  ADDIN EN.CITE (, ), in this study we show that IL-17A has no effect on COX-2 mRNA gene expression, instead IL-17A acts to enhance the stability of COX-2 protein induced by TNF. 
Diverse stimuli are known to induce COX-2 () and the half-life (t1/2) of the protein is known to be relatively short-lived. This allows the protein to be rapidly upregulated and labile prostanoids produced, and then rapidly switched off to limit the amount of prostanoids produced. In cell types apart from ASM, the t1/2 for COX-2 varies from 2-7 h (see review by ()) where Kang et al. comments that “COX-2 protein degradation is specifically programmed to limit the COX-2”. Herein we perform cycloheximide chase experiments and demonstrate, for the first time in ASM cells, that the t1/2 of TNFα-induced COX-2 (defined here as time (h) taken to reach 50% of COX-2 protein levels observed before cycloheximide treatment) is between 1-2 h (as shown in Figure 4). In contrast, COX-2 protein produced after stimulation with IL-17A + TNFα is comparatively stable and does not degrade to levels below 50% over the evaluation period examined (up to 16 h post-cycloheximide treatment). In the presence of IL-17A, TNFα-induced COX-2 protein is sustained and remains at plateau of ~ 70%, compared to ~ 30% in the absence of IL-17A. The mechanisms responsible for enhanced protein stability may involve post-translational modifications and endoplasmic reticulum-associated degradation systems  ADDIN EN.CITE (, ), and in cell types apart from ASM, degradation by the 26S proteasome has been shown to play a role  ADDIN EN.CITE (). Further studies are warranted as these molecular mechanisms may be amenable to pharmacological intervention as members of the proteasomal machinery may prove to be important drug targets to combat inflammatory disease in the future  ADDIN EN.CITE ().
We show that IL-17A has a substantial impact on PGE2 secretion from ASM cells by increasing TNF-induced COX-2 protein upregulation in a sustained manner. PGE2 is a multifunctional prostanoid with both beneficial and adverse effects in respiratory disease. Early studies revealed that PGE2 has bronchodilatory and anti-inflammatory effects in human airways  ADDIN EN.CITE (, ). This is consistent with the ability of PGE2 to act via receptor-mediated pathways to enhance cAMP  ADDIN EN.CITE (). However, PGE2 can also cause desensitization of the β2-adrenergic receptor on ASM cells (reviewed in  ADDIN EN.CITE (, )), and we have shown that pro-inflammatory mediators and infectious stimuli (acting via TLRs)  ADDIN EN.CITE () cause PGE2-dependent heterologous desensitization of the β2-adrenergic receptor in vitro. In this way, PGE2 may curtail the beneficial bronchodilatory actions of β2-agonists. Given that hyporesponsiveness to bronchodilators is a hallmark feature of exacerbation in respiratory disease (), and IL-17A has been shown to drive infectious exacerbation  ADDIN EN.CITE (), we sought to examine the impact of IL-17A on β2-adrenergic desensitization. Utilizing our established method  ADDIN EN.CITE (, ) for assessing β2-adrenergic desensitization in ASM cells by measuring β2-agonist-induced cAMP production, we confirmed that PGE2 caused desensitization, and as expected due to its inability to induce PGE2, IL-17A did not. Consistent with the aforementioned ability of PGE2 to induce cAMP, it was not possible to demonstrate an effect of IL-17A + TNF on β2-adrenergic desensitization, as IL-17A + TNF significantly induced cAMP in a COX-2/PGE2-dependent manner. 
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Figure 1. IL-17A augments TNF-induced PGE2 secretion, but does not increase TNF-induced COX-2 mRNA expression. Growth-arrested ASM cells were treated with vehicle, IL-17A (10 ng/ml), TNF (10 ng/ml), or IL-17A + TNF (both at 10 ng/ml), for 0, 1, 2, 4, 8, and 24 h. (A) PGE2 secretion was measured by EIA. (B) COX-2 mRNA expression was quantified by real-time RT-PCR (results expressed as fold increase compared to vehicle-treated cells at 0 h). Statistical analysis was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a significant effect of TNF on PGE2 secretion or COX-2 mRNA expression, and § denotes a significant effect of IL-17A on TNF-induced PGE2 secretion (P<0.05)). Data are mean±SEM values from n=5 primary ASM cell cultures.

Figure 2. IL-17A increases TNF-induced COX-2 protein upregulation. Growth-arrested ASM cells were treated with vehicle, IL-17A (10 ng/ml), TNF (10 ng/ml), or IL-17A + TNF (both at 10 ng/ml), for 0, 1, 2, 4, 8, and 24 h. COX-2 protein was detected by Western blotting (compared to -tubulin as a loading control), where (A) is a representative blot (vehicle and IL-17A did not induce COX-2 protein – data not shown) and (B) is densitometric analysis of COX-2 protein upregulation (results normalised with -tubulin then expressed as fold increase compared to vehicle-treated cells at 0 h). Statistical analysis was performed by two-way ANOVA then Bonferroni's post-test (where * denotes a significant effect of TNF on COX-2 protein upregulation, and § denotes a significant effect of IL-17A on TNF-induced COX-2 protein upregulation (P<0.05)). Data are mean±SEM values from n=4 primary ASM cell cultures.

Figure 3. Proteasome inhibitors increase TNF-induced COX-2 protein and PGE2 secretion. Growth-arrested ASM cells were pretreated for 30 min with vehicle, bortezomib (10 nM), or MG-132 (10 µM) before stimulation with TNF (10 ng/ml) for 0, 1, 2, 4, 8, and 24 h. (A, B) COX-2 protein was detected by Western blotting at 24 h (compared to -tubulin as a loading control), where (A) is a representative blot and (B) is densitometric analysis of COX-2 protein upregulation (results normalised with -tubulin then expressed as fold increase compared to TNF-treated cells at 0 h). Statistical analysis was performed with two-way ANOVA then Bonferroni's post-test (where § denotes a significant effect of proteasome inhibition on TNF-induced COX-2 protein upregulation (P<0.05)). (C) PGE2 secretion at 24 h was measured by EIA (results expressed as fold increase compared to vehicle-treated cells at 0 h). Statistical analysis was performed one-way ANOVA then Fisher’s post-hoc multiple comparison test (where § denotes a significant effect of proteasome inhibition on TNF-induced PGE2 secretion (P<0.05)). Data are mean±SEM values from n=6 primary ASM cell cultures.

Figure 4. IL-17A increases TNF-induced COX-2 protein stability. Growth-arrested ASM cells were treated with TNF (10 ng/ml) or IL-17A + TNF (both at 10 ng/ml) for 8 h. Cells were then washed and treated with 20 µg/ml cycloheximide to inhibit further protein translation. Cell lysates were then prepared at 0, 1, 2, 4, 6 and 16 h and COX-2 protein quantified by Western blotting (compared to -tubulin as a loading control). COX-2 protein levels at each time point was measured by densitometry and expressed as a percentage of COX-2 at 0 h (i.e. time of treatment with cycloheximide). Statistical analysis was performed by two-way ANOVA then Bonferroni's post-test (where § denotes a significant effect of IL-17A on TNF-induced COX-2 protein stability (P<0.05)). Data are mean±SEM values with non-linear regression curve fit from n=6 primary ASM cell cultures.

Figure 5. TNFα-induced IκB-α degradation was unaffected by IL-17A. Growth-arrested ASM cells were treated with vehicle, IL-17A (10 ng/ml), TNF (10 ng/ml), or IL-17A + TNF (both at 10 ng/ml), for 0, 15, 30, 45 and 60 min. IκB-α was analysed by Western blotting compared to -tubulin as a loading control. Results are representative of n=3 primary ASM cell cultures.

Figure 6. Heterologous β2-adrenergic desensitization as measured by inhibition of β2-agonist-induced cAMP production in ASM cells: effects of IL-17A ± TNF. (A, B) Growth-arrested ASM cells were pretreated for 24 h with vehicle, 100 nM PGE2, IL-17A (10 ng/ml), or IL-17A + TNF (both at 10 ng/ml). Desensitization of the β2-adrenergic receptor was assessed by measuring production of cAMP (pmol/ml) in response to stimulation with (A) 10 µM salbutamol or (B) 10 nM formoterol for 15 min, compared to vehicle, in the presence of the pan-phosphodiesterase inhibitor IBMX. In parallel studies using conditions outlined above: (C) cells were pretreated for 24 h with vehicle, IL-17A, or IL-17A + TNF, and cAMP production (pmol/ml) measured; (D) cells were pretreated for 1 h with vehicle or celecoxib (10 µM) and the effect on % IL-17A + TNF-induced cAMP assessed. Statistical analysis was performed using Student's unpaired t test (where * denotes a significant effect on cAMP production and § denotes significant repression (P<0.05)). Data are mean±SEM values from n=6 primary ASM cell cultures.
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